The Cognitive Neurology of Corticobasal Degeneration and Progressive Supranuclear Palsy

doi:10.1017/9781108985055.013

Chapter 13 - The Cognitive Neurology of Corticobasal Degeneration and Progressive Supranuclear Palsy

from Section 2 - The Dementias

Published online by Cambridge University Press: 17 November 2025

Suzee E. Lee and

Carolyn Fredericks

Edited by

Bruce L. Miller and

Bradley F. Boeve

Show author details

Bruce L. Miller: Affiliation:
University of California, San Francisco
Bradley F. Boeve: Affiliation:
Mayo Clinic, Minnesota

Book contents

Get access

Summary

Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) are neurodegenerative diseases associated with tau protein abnormalities. CBD is characterized by asymmetric parkinsonism, apraxia, and cognitive and behavioral symptoms. PSP is characterized by supranuclear gaze palsy, postural instability, and cognitive and behavioral changes. Both diseases have heterogeneous clinical presentations and can be difficult to diagnose. There are currently no disease-modifying treatments available for CBD or PSP, but symptomatic relief can be provided through medications and therapy. Research is ongoing to develop biomarkers and therapies for these diseases.

Keywords

corticobasal degeneration progressive supranuclear palsy tauopathies clinical syndromes cognitive and behavioral symptoms epidemiology genetics pathology clinicopathological correlates diagnostic studies therapies

Information

Type: Chapter
Information: The Behavioral Neurology of Dementia , pp. 199 - 214

DOI: https://doi.org/10.1017/9781108985055.013 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Rebeiz, JJ, Kolodny, EH, Richardson, EP Jr. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol. 1968 Jan;18(1):20–33.10.1001/archneur.1968.00470310034003CrossRef Google Scholar PubMed

Gibb, WR, Luthert, PJ, Marsden, CD. Corticobasal degeneration. Brain. 1989 Oct;112 (Pt 5):1171–1192.10.1093/brain/112.5.1171CrossRef Google Scholar PubMed

Riley, DE, Lang, AE, Lewis, A, et al. Cortical-basal ganglionic degeneration. Neurology. 1990 Aug;40(8):1203–1212.10.1212/WNL.40.8.1203CrossRef Google Scholar PubMed

Constantinidis, J, Richard, J, Tissot, R. Pick’s disease. Histological and clinical correlations. Eur Neurol. 1974;11(4):208–217.10.1159/000114320CrossRef Google Scholar PubMed

Lee, SE, Rabinovici, GD, Mayo, MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011 Aug;70(2):327–340.10.1002/ana.22424CrossRef Google Scholar PubMed

Vanvoorst, WA, Greenaway, MC, Boeve, BF, et al. Neuropsychological findings in clinically atypical autopsy confirmed corticobasal degeneration and progressive supranuclear palsy. Parkinsonism Relat Disord. 2008;14(4):376–378.10.1016/j.parkreldis.2007.09.006CrossRef Google Scholar PubMed

Grimes, DA, Lang, AE, Bergeron, CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology. 1999 Dec 10;53(9):1969–1674.10.1212/WNL.53.9.1969CrossRef Google Scholar

Murray, R, Neumann, M, Forman, MS, et al. Cognitive and motor assessment in autopsy-proven corticobasal degeneration. Neurology. 2007 Apr 17;68(16):1274–1283.10.1212/01.wnl.0000259519.78480.c3CrossRef Google Scholar PubMed

Kertesz, A, McMonagle, P, Blair, M, Davidson, W, Munoz, DG. The evolution and pathology of frontotemporal dementia. Brain. 2005 Sep;128(Pt 9):1996–2005.10.1093/brain/awh598CrossRef Google Scholar PubMed

Geda, YE, Boeve, BF, Negash, S, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci. 2007 Winter;19(1):77–80.10.1176/jnp.2007.19.1.77CrossRef Google Scholar PubMed

Togasaki, DM, Tanner, CM. Epidemiologic aspects. Adv Neurol. 2000;82:53–59.Google Scholar PubMed

Morimatsu, M, Negoro, K. [Provisional diagnostic criteria of corticobasal degeneration (CBD) and the survey of patients with CBD in Japan]. Rinsho Shinkeigaku. 2002 Nov;42(11):1150–1153.Google Scholar PubMed

Wenning, GK, Litvan, I, Jankovic, J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. 1998 Feb;64(2):184–189.10.1136/jnnp.64.2.184CrossRef Google Scholar PubMed

Armstrong, MJ, Litvan, I, Lang, AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496–503.10.1212/WNL.0b013e31827f0fd1CrossRef Google Scholar PubMed

Bugiani, O, Murrell, JR, Giaccone, G, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol. 1999 Jun;58(6):667–677.10.1097/00005072-199906000-00011CrossRef Google Scholar

Spillantini, MG, Yoshida, H, Rizzini, C, 9 et al. A novel tau mutation (N296 N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol. 2000 Dec;48(6):939–943.10.1002/1531-8249(200012)48:6<939::AID-ANA17>3.0.CO;2-13.0.CO;2-1>CrossRef Google Scholar

Rossi, G, Marelli, C, Farina, L, et al. The G389 R mutation in the MAPT gene presenting as sporadic corticobasal syndrome. Mov Disord. 2008 Apr 30;23(6):892–895.10.1002/mds.21970CrossRef Google Scholar

Yu, CE, Bird, TD, Bekris, LM, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol. 2010 Feb;67(2):161–170.10.1001/archneurol.2009.328CrossRef Google Scholar PubMed

Rohrer, JD, Beck, J, Warren, JD, et al. Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation. J Neurol Neurosurg Psychiatry. 2009 Nov;80(11):1297–1298.10.1136/jnnp.2008.169383CrossRef Google Scholar PubMed

Masellis, M, Momeni, P, Meschino, W, et al. Novel splicing mutation in the progranulin gene causing familial corticobasal syndrome. Brain. 2006 Nov;129(Pt 11):3115–3123.10.1093/brain/awl276CrossRef Google Scholar PubMed

Conrad, C, Amano, N, Andreadis, A, et al. Differences in a dinucleotide repeat polymorphism in the tau gene between Caucasian and Japanese populations: implication for progressive supranuclear palsy. Neurosci Lett. 1998 Jul 3;250(2):135–137.10.1016/S0304-3940(98)00417-0CrossRef Google Scholar

Evans, W, Fung, HC, Steele, J, et al. The tau H2 haplotype is almost exclusively Caucasian in origin. Neurosci Lett. 2004 Oct 21;369(3):183–185.10.1016/j.neulet.2004.05.119CrossRef Google Scholar PubMed

Baker, M, Litvan, I, Houlden, H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet. 1999 Apr;8(4):711–715.10.1093/hmg/8.4.711CrossRef Google Scholar PubMed

Houlden, H, Baker, M, Morris, HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001 Jun 26;56(12):1702–1706.10.1212/WNL.56.12.1702CrossRef Google Scholar

Verpillat, P, Camuzat, A, Hannequin, D, et al. Association between the extended tau haplotype and frontotemporal dementia. Arch Neurol. 2002 Jun;59(6):935–939.10.1001/archneur.59.6.935CrossRef Google Scholar PubMed

Hughes, A, Mann, D, Pickering-Brown, S. Tau haplotype frequency in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Exp Neurol. 2003 May;181(1):12–16.10.1016/S0014-4886(03)00024-4CrossRef Google Scholar PubMed

Sobrido, MJ, Abu-Khalil, A, Weintraub, S, et al. Possible association of the tau H1/H1 genotype with primary progressive aphasia. Neurology. 2003 Mar 11;60(5):862–864.10.1212/01.WNL.0000049473.36612.F2CrossRef Google Scholar PubMed

Kouri, N, Ross, OA, Dombroski, B, et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun. 2015 Jun 16;6:7247.10.1038/ncomms8247CrossRef Google Scholar PubMed

Kertesz, A, Martinez-Lage, P, Davidson, W, Munoz, DG. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology. 2000 Nov 14;55(9):1368–1375.10.1212/WNL.55.9.1368CrossRef Google Scholar PubMed

Graham, NL, Bak, TH, Hodges, JR. Corticobasal degeneration as a cognitive disorder. Mov Disord. 2003 Nov;18(11):1224–1232.10.1002/mds.10536CrossRef Google Scholar PubMed

Pillon, B, Blin, J, Vidailhet, M, et al. The neuropsychological pattern of corticobasal degeneration: comparison with progressive supranuclear palsy and Alzheimer’s disease. Neurology. 1995 Aug;45(8):1477–1483.10.1212/WNL.45.8.1477CrossRef Google Scholar PubMed

Belfor, N, Amici, S, Boxer, AL, et al. Clinical and neuropsychological features of corticobasal degeneration. Mech Ageing Dev. 2006 Feb;127(2):203–207.10.1016/j.mad.2005.09.013CrossRef Google Scholar PubMed

Rascovsky, K, Hodges, JR, Knopman, D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. Aug 2;2011;134(Pt 9):2456–2477.10.1093/brain/awr179CrossRef Google Scholar PubMed

Gorno-Tempini, ML, Hillis, AE, Weintraub, S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011 Mar 15;76(11):1006–1014.10.1212/WNL.0b013e31821103e6CrossRef Google Scholar PubMed

Boeve, BF, Maraganore, DM, Parisi, JE, et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology. 1999 Sep 11;53(4):795–800.10.1212/WNL.53.4.795CrossRef Google Scholar PubMed

Josephs, KA, Dickson, DW. Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank. Mov Disord. 2003 Sep;18(9):1018–1026.10.1002/mds.10488CrossRef Google Scholar

Josephs, KA, Petersen, RC, Knopman, DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006 Jan 10;66(1):41–48.10.1212/01.wnl.0000191307.69661.c3CrossRef Google Scholar PubMed

Rohrer, JD, Geser, F, Zhou, J, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010 Dec 14;75(24):2204–2211.10.1212/WNL.0b013e318202038cCrossRef Google Scholar PubMed

Spinelli, EG, Mandelli, ML, Miller, ZA, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017 Mar 20;81(3):430–443.10.1002/ana.24885CrossRef Google Scholar PubMed

Wakabayashi, K, Oyanagi, K, Makifuchi, T, et al. Corticobasal degeneration: etiopathological significance of the cytoskeletal alterations. Acta Neuropathol. 1994;87(6):545–553.10.1007/BF00293314CrossRef Google Scholar PubMed

Buee Scherrer, V, Hof, PR, Buee, L, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick’s disease. Acta Neuropathol. 1996;91(4):351–359.10.1007/s004010050436CrossRef Google Scholar PubMed

Grundke-Iqbal, I, Iqbal, K, Quinlan, M, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986 May 5;261(13):6084–6089.10.1016/S0021-9258(17)38495-8CrossRef Google Scholar PubMed

Witman, GB, Cleveland, DW, Weingarten, MD, Kirschner, MW. Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A. 1976 Nov;73(11):4070–4074.10.1073/pnas.73.11.4070CrossRef Google Scholar PubMed

Cairns, NJ, Bigio, EH, Mackenzie, IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007 Jul;114(1):5–22.10.1007/s00401-007-0237-2CrossRef Google Scholar

Dickson, DW, Bergeron, C, Chin, SS, et al. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002 Nov;61(11):935–946.10.1093/jnen/61.11.935CrossRef Google Scholar PubMed

Komori, T, Arai, N, Oda, M, et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 1998 Oct;96(4):401–840.10.1007/s004010050911CrossRef Google Scholar

Feany, MB, Dickson, DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol. 1995 Jun;146(6):1388–1396.Google Scholar PubMed

Litvan, I, Agid, Y, Goetz, C, et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology. 1997 Jan;48(1):119–125.10.1212/WNL.48.1.119CrossRef Google Scholar PubMed

Mackenzie, IR, Neumann, M, Bigio, EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010 Jan;119(1):1–4.10.1007/s00401-009-0612-2CrossRef Google Scholar PubMed

Josephs, KA, Duffy, JR, Strand, EA, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006 Jun;129(Pt 6):1385–1398.10.1093/brain/awl078CrossRef Google Scholar PubMed

Ling, H, O’Sullivan, SS, Holton, JL, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010 Jul;133(Pt 7):2045–2057.10.1093/brain/awq123CrossRef Google Scholar PubMed

Hu, WT, Rippon, GW, Boeve, BF, et al. Alzheimer’s disease and corticobasal degeneration presenting as corticobasal syndrome. Mov Disord. 2009 Jul 15;24(9):1375–1379.10.1002/mds.22574CrossRef Google Scholar PubMed

Shelley, BP, Hodges, JR, Kipps, CM, Xuereb, JH, Bak, TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord. 2009 Aug 15;24(11):1593–1599.10.1002/mds.22558CrossRef Google Scholar

Sha, SJ, Ghosh, PM, Lee, SE, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther. 2015;7(1):8.10.1186/s13195-014-0093-yCrossRef Google Scholar PubMed

Steele, JC, Richardson, JC, Olszewski, J. Progressive supranuclear palsy. a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964 Apr;10:333–359.10.1001/archneur.1964.00460160003001CrossRef Google Scholar PubMed

Chambers, CB, Lee, JM, Troncoso, JC, Reich, S, Muma, NA. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer’s disease. Ann Neurol. 1999 Sep;46(3):325–332.10.1002/1531-8249(199909)46:3<325::AID-ANA8>3.0.CO;2-V3.0.CO;2-V>CrossRef Google Scholar

Steele, JC. Progressive supranuclear palsy. Brain. 1972;95(4):693–704.Google Scholar PubMed

David, NJ, Mackey, EA, Smith, JL. Further observations in progressive supranuclear palsy. Neurology. 1968 Apr;18(4):349–356.10.1212/WNL.18.4.349CrossRef Google Scholar PubMed

Litvan, I, Agid, Y, Calne, D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1–9.10.1212/WNL.47.1.1CrossRef Google Scholar PubMed

Höglinger, GU, Respondek, G, Stamelou, M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864.10.1002/mds.26987CrossRef Google Scholar PubMed

Osaki, Y, Ben-Shlomo, Y, Lees, AJ, et al. Accuracy of clinical diagnosis of progressive supranuclear palsy. Movement Disord. 2004 Feb;19(2):181–189.10.1002/mds.10680CrossRef Google Scholar PubMed

Litvan, I, Agid, Y, Jankovic, J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology. 1996 Apr;46(4):922–930.10.1212/WNL.46.4.922CrossRef Google Scholar PubMed

Hughes, AJ, Daniel, SE, Ben-Shlomo, Y, Lees, AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002 Apr;125(Pt 4):861–870.10.1093/brain/awf080CrossRef Google Scholar

Daniel, SE, de Bruin, VM, Lees, AJ. The clinical and pathological spectrum of Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy): a reappraisal. Brain. 1995 Jun;118 (Pt 3):759–770.10.1093/brain/118.3.759CrossRef Google Scholar PubMed

Litvan, I, Grimes, DA, Lang, AE, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol. 1999 Sep;246 (Suppl 2):II1–II5.10.1007/BF03161075CrossRef Google Scholar PubMed

Morris, HR, Gibb, G, Katzenschlager, R, et al. Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain. 2002 May;125(Pt 5):969–975.10.1093/brain/awf109CrossRef Google Scholar PubMed

Respondek, G, Stamelou, M, Kurz, C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014 Dec;29(14):1758–1766.10.1002/mds.26054CrossRef Google Scholar PubMed

Wadia, PM, Lang, AE. The many faces of corticobasal degeneration. Parkinsonism Relat Disord. 2007;13(Suppl 3):S336–S340.10.1016/S1353-8020(08)70027-0CrossRef Google Scholar PubMed

Nath, U, Ben-Shlomo, Y, Thomson, RG, et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain. 2001 Jul;124(Pt 7):1438–1449.10.1093/brain/124.7.1438CrossRef Google Scholar PubMed

Schrag, A, Ben-Shlomo, Y, Quinn, NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999 Nov 20;354(9192):1771–1775.10.1016/S0140-6736(99)04137-9CrossRef Google Scholar PubMed

Bower, JH, Maraganore, DM, McDonnell, SK, Rocca, WA. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology. 1997 Nov;49(5):1284–1288.10.1212/WNL.49.5.1284CrossRef Google Scholar PubMed

Takigawa, H, Kitayama, M, Wada-Isoe, K, Kowa, H, Nakashima, K. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav. 2016 Dec;6(12):e00557.10.1002/brb3.557CrossRef Google Scholar PubMed

Maher, ER, Lees, AJ. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1986 Jul;36(7):1005–1008.10.1212/WNL.36.7.1005CrossRef Google Scholar PubMed

Golbe, LI, Davis, PH, Schoenberg, BS, Duvoisin, RC. Prevalence and natural history of progressive supranuclear palsy. Neurology. 1988 Jul;38(7):1031–1034.10.1212/WNL.38.7.1031CrossRef Google Scholar PubMed

Donker Kaat, L, Boon, AJ, Azmani, A, et al. Familial aggregation of parkinsonism in progressive supranuclear palsy. Neurology. 2009 Jul 14;73(2):98–105.10.1212/WNL.0b013e3181a92bccCrossRef Google Scholar PubMed

Dickson, DW, Rademakers, R, Hutton, ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol. 2007 Jan;17(1):74–82.10.1111/j.1750-3639.2007.00054.xCrossRef Google Scholar PubMed

Hoglinger, GU, Melhem, NM, Dickson, DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet. 2011 Jul;43(7):699–705.10.1038/ng.859CrossRef Google Scholar PubMed

Bonham, LW, Karch, CM, Fan, CC, et al. CXCR4 involvement in neurodegenerative diseases. Transl Psychiatry. 2018 Apr 11;8(1):73.10.1038/s41398-017-0049-7CrossRef Google Scholar PubMed

Zhao, Y, Tseng, I-C, Heyser, CJ, et al. Appoptosin-mediated caspase cleavage of tau contributes to progressive supranuclear palsy pathogenesis. Neuron. 2015 Sep 2;87(5):963–975.10.1016/j.neuron.2015.08.020CrossRef Google Scholar PubMed

Boxer, AL, Garbutt, S, Seeley, WW, et al. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol. Apr;69(4):509–517.10.1001/archneurol.2011.1021CrossRef Google Scholar

Rivaud-Pechoux, S, Vidailhet, M, Gallouedec, G, et al. Longitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy. Neurology. 2000 Mar 14;54(5):1029–1032.10.1212/WNL.54.5.1029CrossRef Google Scholar PubMed

Garbutt, S, Matlin, A, Hellmuth, J, et al. Oculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer’s disease. Brain. 2008 May;131(Pt 5):1268–1281.10.1093/brain/awn047CrossRef Google Scholar PubMed

Vidailhet, M, Rivaud, S, Gouider-Khouja, N, et al. Eye movements in parkinsonian syndromes. Ann Neurol. 1994 Apr;35(4):420–426.10.1002/ana.410350408CrossRef Google Scholar PubMed

Rottach, KG, Riley, DE, DiScenna, AO, Zivotofsky, AZ, Leigh, RJ. Dynamic properties of horizontal and vertical eye movements in parkinsonian syndromes. Ann Neurol. 1996 Mar;39(3):368–377.10.1002/ana.410390314CrossRef Google Scholar PubMed

Golbe, LI, Davis, PH, Lepore, FE. Eyelid movement abnormalities in progressive supranuclear palsy. Mov Disord. 1989;4(4):297–302.10.1002/mds.870040402CrossRef Google Scholar PubMed

Nath, U, Ben-Shlomo, Y, Thomson, RG, Lees, AJ, Burn, DJ. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003 Mar 25;60(6):910–916.10.1212/01.WNL.0000052991.70149.68CrossRef Google Scholar PubMed

Donker Kaat, L, Boon, AJ, Kamphorst, W, et al. Frontal presentation in progressive supranuclear palsy. Neurology. 2007 Aug 21;69(8):723–729.10.1212/01.wnl.0000267643.24870.26CrossRef Google Scholar PubMed

Kertesz, A, McMonagle, P. Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy. J Neurol Sci. 2010 Feb 15;289(1–2):138–143.10.1016/j.jns.2009.08.036CrossRef Google Scholar PubMed

Litvan, I, Mega, MS, Cummings, JL, Fairbanks, L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996 Nov;47(5):1184–1189.10.1212/WNL.47.5.1184CrossRef Google Scholar PubMed

Pillon, B, Gouider-Khouja, N, Deweer, B, et al. Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):174–179.10.1136/jnnp.58.2.174CrossRef Google Scholar PubMed

Lantos, PL. The neuropathology of progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:137–152.10.1007/978-3-7091-6641-3_11CrossRef Google Scholar PubMed

Williams, DR, de Silva, R, Paviour, DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism. Brain. 2005 Jun;128(Pt 6):1247–1258.10.1093/brain/awh488CrossRef Google Scholar PubMed

Williams, DR, Holton, JL, Strand, C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain. 2007 Jun;130(Pt 6):1566–1576.10.1093/brain/awm104CrossRef Google Scholar PubMed

Williams, DR, Holton, JL, Strand, K, Revesz, T, Lees, AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Move Disord. 2007 Nov 15;22(15):2235–2241.10.1002/mds.21698CrossRef Google Scholar PubMed

Dickson, DW, Ahmed, Z, Algom, AA, Tsuboi, Y, Josephs, KA. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010 Aug;23(4):394–400.10.1097/WCO.0b013e32833be924CrossRef Google Scholar PubMed

Tagliavini, F, Pilleri, G, Bouras, C, Constantinidis, J. The basal nucleus of Meynert in patients with progressive supranuclear palsy. Neurosci Lett. 1984 Jan 27;44(1):37–42.10.1016/0304-3940(84)90217-9CrossRef Google Scholar PubMed

Nishimura, M, Namba, Y, Ikeda, K, Oda, M. Glial fibrillary tangles with straight tubules in the brains of patients with progressive supranuclear palsy. Neurosci Lett. 1992 Aug 31;143(1–2):35–38.10.1016/0304-3940(92)90227-XCrossRef Google Scholar PubMed

Matsusaka, H, Ikeda, K, Akiyama, H, et al. Astrocytic pathology in progressive supranuclear palsy: significance for neuropathological diagnosis. Acta Neuropathol. 1998 Sep;96(3):248–252.10.1007/s004010050891CrossRef Google Scholar PubMed

Arima, K, Nakamura, M, Sunohara, N, et al. Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol. 1997 Jun;93(6):558–566.10.1007/s004010050652CrossRef Google Scholar PubMed

Arai, H, Morikawa, Y, Higuchi, M, et al. Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun. 1997 Jul 18;236(2):262–264.10.1006/bbrc.1997.6908CrossRef Google Scholar PubMed

Noguchi, M, Yoshita, M, Matsumoto, Y, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci. 2005 Oct 15;237(1–2):61–65.10.1016/j.jns.2005.05.015CrossRef Google Scholar PubMed

Urakami, K, Wada, K, Arai, H, et al. Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci. 2001 Jan 15;183(1):95–98.10.1016/S0022-510X(00)00480-9CrossRef Google Scholar PubMed

Mitani, K, Furiya, Y, Uchihara, T, et al. Increased CSF tau protein in corticobasal degeneration. J Neurol. 1998 Jan;245(1):44–46.10.1007/s004150050173CrossRef Google Scholar PubMed

Rojas, JC, Bang, J, Lobach, IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 Jan 23;90(4):e273–e281.10.1212/WNL.0000000000004859CrossRef Google Scholar PubMed

Verbeek, MM, Abdo, WF, De Jong, D, et al. Cerebrospinal fluid Abeta42 levels in multiple system atrophy. Mov Disord. 2004 Feb;19(2):238–240; author reply 240–241.10.1002/mds.10687CrossRef Google Scholar PubMed

Holmberg, B, Johnels, B, Blennow, K, Rosengren, L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Mov Disord. 2003 Feb;18(2):186–190.10.1002/mds.10321CrossRef Google Scholar PubMed

Brettschneider, J, Petzold, A, Sussmuth, SD, et al. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord. 2006 Dec;21(12):2224–2227.10.1002/mds.21124CrossRef Google Scholar PubMed

Rojas, JC, Karydas, A, Bang, J, et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol. 2016 Mar;3(3):216–225.10.1002/acn3.290CrossRef Google Scholar PubMed

Whitwell, JL, Jack, CR, Boeve, BF, et al. Imaging correlates of pathology in corticobasal syndrome. Neurology. 2010 Nov 23;75(21):1879–1887.10.1212/WNL.0b013e3181feb2e8CrossRef Google Scholar PubMed

Oba, H, Yagishita, A, Terada, H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology. 2005 Jun 28;64(12):2050–2055.10.1212/01.WNL.0000165960.04422.D0CrossRef Google Scholar PubMed

Quattrone, A, Nicoletti, G, Messina, D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology. 2008 Jan;246(1):214–221.10.1148/radiol.2453061703CrossRef Google Scholar PubMed

Brenneis, C, Seppi, K, Schocke, M, et al. Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):246–249.Google Scholar PubMed

Boxer, AL, Geschwind, MD, Belfor, N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol. 2006 Jan;63(1):81–86.10.1001/archneur.63.1.81CrossRef Google Scholar PubMed

Price, S, Paviour, D, Scahill, R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson’s disease. NeuroImage. 2004 Oct;23(2):663–669.10.1016/j.neuroimage.2004.06.013CrossRef Google Scholar PubMed

Josephs, KA, Whitwell, JL, Dickson, DW, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging. 2008 Feb;29(2):280–289.10.1016/j.neurobiolaging.2006.09.019CrossRef Google Scholar PubMed

Okamura, N, Furumoto, S, Fodero-Tavoletti, MT, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014 Jun;137(Pt 6):1762–1771.10.1093/brain/awu064CrossRef Google Scholar PubMed

Sander, K, Lashley, T, Gami, P, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer’s disease, primary tauopathies, and other dementias. Alzheimers Dement. 2016 Nov 1;12(11):1116–1124.10.1016/j.jalz.2016.01.003CrossRef Google Scholar PubMed

Marquié, M, Normandin, MD, Vanderburg, CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5):787–800.10.1002/ana.24517CrossRef Google Scholar PubMed

Lowe, VJ, Curran, G, Fang, P, et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun. 2016 Jun 13;4(1):58.10.1186/s40478-016-0315-6CrossRef Google Scholar PubMed

Cho, H, Choi, JY, Hwang, MS, et al. Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord. 2017;32(1):134–140.10.1002/mds.26844CrossRef Google Scholar PubMed

Passamonti, L, Vázquez Rodríguez, P, Hong, YT, et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017 Mar 1;140(3):781–791.Google Scholar PubMed

Schonhaut, DR, McMillan, CT, Spina, S, et al. 18F-Flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: a multicenter study. Ann Neurol. 2017;82(4):622–634.10.1002/ana.25060CrossRef Google Scholar PubMed

Soleimani-Meigooni, DN, Iaccarino, L, La Joie, R, et al. 18F-Flortaucipir PET to autopsy comparisons in Alzheimer’s disease and other neurodegenerative diseases. Brain. 2020 Dec 5;143(11):3477–3494.10.1093/brain/awaa276CrossRef Google Scholar PubMed

Whitwell, JL, Lowe, VJ, Tosakulwong, N, et al. [18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord. 2017 Jan;32(1):124–133.10.1002/mds.26834CrossRef Google Scholar PubMed

Passamonti, L, Vázquez Rodríguez, P, Hong, YT et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy. Brain. 2017 Mar 1;140(3):781–791.Google Scholar PubMed

Coakeley, S, Cho, SS, Koshimori, Y, et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab. 2017 Sep 1;37(9):3150–3160.10.1177/0271678X16683695CrossRef Google Scholar PubMed

Smith, R, Schöll, M, Honer, M, et al. Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathol. 2017 Jan 1;133(1):149–151.10.1007/s00401-016-1650-1CrossRef Google Scholar

Soleimani‐Meigooni, DN, Iaccarino, L, Joie, RL, et al. [18F]Flortaucipir PET to autopsy pathology comparisons in Alzheimer’s disease and other neurodegenerative diseases. Alzheimers Dement. 2020;16(S4):e046262.10.1002/alz.046262CrossRef Google Scholar

Ono, M, Sahara, N, Kumata, K, et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain. 2017 Mar 1;140(3):764–780.Google Scholar PubMed

Endo, H, Shimada, H, Sahara, N, et al. In vivo binding of a tau imaging probe, [11C]PBB3, in patients with progressive supranuclear palsy. Mov Disord. 2019;34(5):744–754.10.1002/mds.27643CrossRef Google Scholar

Ishiki, A, Harada, R, Kai, H, et al. Neuroimaging-pathological correlations of [18F]THK5351 PET in progressive supranuclear palsy. Acta Neuropathol Commun. 2018 Jun 29;6(1):53.10.1186/s40478-018-0556-7CrossRef Google Scholar PubMed

Brendel, M, Barthel, H, van Eimeren, T, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020 Nov 1;77(11):1408–1419.10.1001/jamaneurol.2020.2526CrossRef Google Scholar PubMed

Whitwell, JL, Tosakulwong, N, Schwarz, CG et al. MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov Disord. 2019;34(1):105–113.10.1002/mds.27546CrossRef Google Scholar PubMed

Coughlin, DG, Litvan, I. Progressive supranuclear palsy: advances in diagnosis and management. Parkinsonism Relat Disord. 2020;73:105–116.10.1016/j.parkreldis.2020.04.014CrossRef Google Scholar PubMed

Kompoliti, K, Goetz, CG, Litvan, I, Jellinger, K, Verny, M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998 Aug;55(8):1099–1102.10.1001/archneur.55.8.1099CrossRef Google Scholar PubMed

Stamelou, M, de Silva, R, Arias-Carrion, O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010 Jun;133(Pt 6):1578–1590.10.1093/brain/awq115CrossRef Google Scholar PubMed

Accessibility standard: WCAG 2.1 AA

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

The HTML of this chapter complies with version 2.1 of the Web Content Accessibility Guidelines (WCAG), covering newer accessibility requirements and improved user experiences and achieves the intermediate (AA) level of WCAG compliance, covering a wider range of accessibility requirements.

Content Navigation

Table of contents navigation
Allows you to navigate directly to chapters, sections, or non‐text items through a linked table of contents, reducing the need for extensive scrolling.

Index navigation
Provides an interactive index, letting you go straight to where a term or subject appears in the text without manual searching.

Reading Order & Textual Equivalents

Single logical reading order
You will encounter all content (including footnotes, captions, etc.) in a clear, sequential flow, making it easier to follow with assistive tools like screen readers.

Short alternative textual descriptions
You get concise descriptions (for images, charts, or media clips), ensuring you do not miss crucial information when visual or audio elements are not accessible.

Visual Accessibility

Use of colour is not sole means of conveying information
You will still understand key ideas or prompts without relying solely on colour, which is especially helpful if you have colour vision deficiencies.

Structural and Technical Features

ARIA roles provided
You gain clarity from ARIA (Accessible Rich Internet Applications) roles and attributes, as they help assistive technologies interpret how each part of the content functions.